research A pharmacovigilance study of drug‐reduced male semen quality based on the Food and Drug Administration adverse event reporting system database
Some drugs can reduce male semen quality.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Drug-Induced Hair Loss: Analysis of the Food and Drug Administration’s Adverse Events Reporting System Database
Certain medications, including some immune drugs, contraceptives, and hair loss treatments, are often linked to hair loss.
research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
research Assessing dutasteride-associated sexual dysfunction using the U.S. Food and Drug Administration Adverse Event Reporting System
Dutasteride is linked to a higher chance of sexual dysfunction, especially in younger males and the elderly.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
research Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
Finasteride use is linked to a higher risk of obstructive sleep apnea.
research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
Finasteride increases risk of sleep apnea and insomnia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
research A Gender Hypothesis of sex disparities in adverse drug events
Gendered social factors, not just biology, contribute to sex differences in adverse drug events.
research Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
Finasteride has a higher risk of reproductive side effects than minoxidil.
research Machine Learning--Enhanced Pharmacovigilance Assessment of Cardiac Adverse Events Associated With Minoxidil
Minoxidil is strongly linked to heart problems, and machine learning can improve drug safety checks.
research Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
Finasteride use may increase suicidality risk, especially in young men.
research Are finasteride-related penile curvature/Peyronie’s disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
Finasteride may be linked to Peyronie’s disease, but more research is needed.
research Controversies: Is Finasteride Safety Data Adequately Reported in Published Trials?
Finasteride safety data in trials may be underreported or misrepresented.
research How routine pharmacovigilance failed to identify finasteride’s persistent sexual side effects
Finasteride, a hair loss drug, has unaddressed sexual side effects due to the manufacturer's inadequate safety measures and lack of additional studies.
research Implementing patient safety and quality improvement in dermatology. Part 1: Patient safety science
The document concludes that improving patient safety and quality is increasingly important in dermatology.
research Cognitive dysfunction following finasteride use: a disproportionality analysis of the global pharmacovigilance database
Finasteride use is linked to increased reports of cognitive problems, especially in younger people with hair loss.
research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
research Finasteride Use: Evaluation of Depression and Suicide Risk
Finasteride use may increase depression and suicide risk, especially at 1 mg, so monitoring is advised.
research Assessing the safety of topical minoxidil through disproportionality analysis of FAERS reports
Topical minoxidil may cause more side effects than currently listed, needing updated safety information.
research Sun behaviors and quality of life after first cutaneous melanoma diagnosis
Finasteride use for hair loss is linked to an increased risk of suicidal thoughts and a higher risk of suicide.
research Sun protection policies and behaviors among U.S. child care centers
Finasteride, a hair loss drug, is linked to increased suicidal thoughts, particularly when used for hair loss.
research Association of 5-α reductase inhibitors and sexual dysfunction: A RADAR report
Using hair loss drugs finasteride and dutasteride may cause sexual side effects.
research Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
Methimazole for hyperthyroidism has known and new side effects needing more study for safety.
research En pacientes jóvenes, el uso de finasteride podría asociarse con mayor riesgo de ansiedad, depresión y eventos adversos relacionados con el suicidio
Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
research Adverse events with finasteride or dutasteride: FAERS
Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.